Benitec Biopharma

Benitec Biopharma doses fifth patient, initiates additional trial site for hepatitis C trial

Thursday, April 30, 2015

Benitec Biopharma, a Sydney, Australia-based biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or “expressed RNAi,” has doesed the fifth patient in the company’s first-in-man, phase I/IIa dose escalation clinical trial of TT-034 for hepatitis C virus (HCV) infection at the Duke Clinical Research Unit. The fifth patient is the third and final patient to be dosed in cohort two.

[Read More]

PRC Clinical updates management, launches east coast operations

Friday, March 27, 2015

PRC Clinical, a Silicon-Valley-based CRO, has announced several management and executive appointments effective immediately. Mike Catelani will assume the role of chief financial officer and member of the board of directors. Daniel Head has been appointed to vice president of business operations, and Sue Dowden will assume the position of senior director of clinical operations. Tony Taricco, co-founder and current chief operations officer, has been appointed president and chairman of the board of directors.

[Read More]